SNOA.US Sonoma Pharmaceuticals Inc

Healthcare Pharmaceuticals USA Stocks
0.8466 USD
Close of Nov 17, 2026
0.8000 3.95
Market cap
USD 4.29M
P/E
-
P/B
0.84x
ROE
-12.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2026.

Is SNOA.US undervalued?

Graham number

The Graham number of Sonoma Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Sonoma Pharmaceuticals Inc fundamental analysis

No fundamental analysis for Sonoma Pharmaceuticals Inc yet.

Sonoma Pharmaceuticals Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Sonoma Pharmaceuticals Inc

Sonoma Pharmaceuticals, Inc. develops and produces stabilized hypochlorous acid (HOCl) products for wound and eye care, oral and nasal care, podiatry, animal health care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally. It offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin fisures, sunburn, peeling, and eczema/atopic dermatitis; Gramaderm for the treatm…

Full company profile